These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12295471)

  • 1. Public / private partnership: developing an oral treatment for visceral leishmaniasis.
    Mattock N
    TDR News; 1999 Oct; (60):1-2. PubMed ID: 12295471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in battle against leishmaniasis.
    TDR News; 1998 Oct; (57):2. PubMed ID: 12294756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmaniasis in Africa.
    Davidson R; Croft S
    Afr Health; 1992 Jul; 14(5):18-9. PubMed ID: 12317771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status of research and development for control of tropical diseases: hypocrisy, indifference or lack of coordination].
    Millet P
    Med Trop (Mars); 2006 Dec; 66(6):542-8. PubMed ID: 17286017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TDR collaboration with the pharmaceutical industry.
    Gutteridge WE
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S21-5. PubMed ID: 16730039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDSCAP seeks a private sector solution to the STD self-treatment dilemma.
    Henry K
    Aidscaptions; 1995 Mar; ():26-9. PubMed ID: 12319707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMV: New Medicines for Malaria Venture.
    TDR News; 1999 Feb; (58):2, 4. PubMed ID: 12322122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin B lipid complex available for AIDS related cryptococcal meningitis. South Africa.
    AIDS Wkly; 1993 Oct; ():8-9. PubMed ID: 12345310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global public-private partnerships against neglected diseases: building governance structures for effective outcomes.
    Buckup S
    Health Econ Policy Law; 2008 Jan; 3(Pt 1):31-50. PubMed ID: 18634631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
    Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.